Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis.

What the trial testedas reported · 13,761 people · 2025

Range includes no effect

−22%−47% to +16%

Bigger than 5 in 10 for adverse events & safety

As reported

RR 0.78, 95% CI 0.53–1.16

the abstract, start to end

… risks of any cancer (risk ratio, 0.78; 95% confidence interval, 0.53 …

← favours treatmentfavours comparator →

could be chance

Adverse events & safety

RR 0.780.53–1.16

GIP/GLP-1 & amylin agonistsAdverse events & safety

GIP/GLP-1 & amylin agonists × adverse events & safetyharms?mixed

unlikelylikely

0.00not counted

← favours treatmentfavours comparator →

more certainless certain

1 / 5

2025

2026

this papercites it